1119779-04-2 Usage
Description
3-Bromo-5-isopropoxybenzoic acid is a chemical compound with the molecular formula C11H13BrO3. It is a derivative of benzoic acid, featuring a bromine atom at the 3-position and an isopropoxy group at the 5-position of the benzene ring. This white to off-white crystalline powder is stable under normal conditions of use and storage, but it should be handled with care due to its potential to cause skin and eye irritation.
Uses
Used in Organic Synthesis:
3-Bromo-5-isopropoxybenzoic acid is utilized as a building block in organic synthesis for the creation of various pharmaceuticals and agrochemicals. Its unique structure allows for the development of a wide range of compounds with specific properties and applications.
Used in Pharmaceutical Research:
In pharmaceutical research, 3-Bromo-5-isopropoxybenzoic acid serves as a key intermediate for the synthesis of new drugs. Its presence in the molecular structure can influence the pharmacological activity, making it a valuable component in drug discovery and development processes.
Used as a Reagent:
3-Bromo-5-isopropoxybenzoic acid is also employed as a reagent in the preparation of other organic compounds. Its reactivity and functional groups make it suitable for use in various chemical reactions, contributing to the synthesis of a diverse array of organic products.
Check Digit Verification of cas no
The CAS Registry Mumber 1119779-04-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,1,9,7,7 and 9 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1119779-04:
(9*1)+(8*1)+(7*1)+(6*9)+(5*7)+(4*7)+(3*9)+(2*0)+(1*4)=172
172 % 10 = 2
So 1119779-04-2 is a valid CAS Registry Number.
1119779-04-2Relevant articles and documents
NOVEL ACTIVATORS OF GLUCOKINASE
-
Page/Page column 143-144, (2009/04/25)
The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistence and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
